The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 51 patients with advanced or recurrent endometrial cancer, across 9 leading oncology hospi...
Read moreThe T-cell infiltrate of 47 endometrial tumors has been analyzed with the aim of defining tumor-reactive CD8+ and CD4+ TIL populations that could be very valuable in identifying prognostic and predict...
Read moreResearch led by the Oncological Pathology research group at the Institute for Research in Biomedicine of Lleida (IRBLleida), the University of Lleida (UdL) and the Department of Pathological Anatomy o...
Read morehe results show that this type of surgery can represent a good option for people affected by this syndrome since it supposes a reduction in the incidence of cancer and its mortality.
Read morePromega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug cand...
Read moreAbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...
Read moreAbility Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which vali...
Read moreThe Massachusetts Institute of Technology (MIT) through the Foundation for Innovation and the Prospective Health in Spain (FIPSE) has selected, from among hundreds of proposals, the CEMARK project to ...
Read moreThe group of Biomedical Research in Gynecology of the Vall d'Hebron Research Institute (VHIR), led by Dr. Antonio Gil, has received one of 20 grants from the 2nd edition of CaixaImpulse, awarded by th...
Read moreABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...
Read moreCollaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.
Read morePresented the results of a research project in IRBLleida in endometrial cancer
Read more